Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
Amir T. Fathi(University of Southern California), Yi‐Bin Chen(Massachusetts General Hospital), Andrew M. Brunner(Harvard University), Kaitlyn Fishman(Harvard University), Seth A. Wander(Harvard University), Meghan Burke(Harvard University), Nicole Hermance(Worcester Polytechnic Institute), Kristin McGregor(Harvard University), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Timothy A. Graubert(Massachusetts General Hospital), Christine Connolly(Massachusetts General Hospital), Gabriela Hobbs(Massachusetts General Hospital), Amity L. Manning(Worcester Polytechnic Institute), Traci M. Blonquist(Harvard University), Meghan Bergeron(Harvard University), Ashley Perry(Harvard University), Tina T. Som(Harvard University), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Jeffrey G. Supko(Harvard University), Aura Y. Ramos(Harvard University), Julia Foster(Harvard University), Regina Silver(Harvard University), Donna Neuberg(Otsuka (Japan)), Christelle Joseph(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 43